LDL-C still high in autosomal recessive hypercholesterolemia

January 19, 2018

(HealthDay)—For patients with autosomal recessive hypercholesterolemia (ARH), low-density lipoprotein cholesterol (LDL-C) levels remain high despite intensive treatment, according to a study published in the Jan. 23 issue of the Journal of the American College of Cardiology.

Laura D'Erasmo, M.D., Ph.D., from the Sapienza University of Rome, and colleagues obtained data for 52 patients with ARH and assessed changes in lipid management, achievement of LDL-C goals, and .

The researchers observed an increase in the use of high-intensity statin and ezetimibe in combination with lipoprotein apheresis during a mean follow-up of 14.1±7.3 years; lomatipide was added in six patients. At nadir, the mean LDL-C was 164±85.1 mg/dL (−69.6 percent from baseline); a better response was seen in patients taking lomitapide (−88.3 percent). LDL-C of <100 mg/dL was reached by 23.1 percent of patients. Incident atherosclerotic cardiovascular disease (ASCVD) occurred in 26.9 percent of patients during follow-up, and 11.5 percent had a new diagnosis of aortic valve stenosis. There were no cases of incident stroke. Major predictors of incident ASCVD included age (≥30 years) and presence of coronary artery disease at diagnosis.

"Despite intensive treatment, LDL-C in ARH remains far from targets, and this translates into a poor long-term cardiovascular prognosis," the authors write. "Our data highlight the importance of an early diagnosis and treatment and confirm the fact that an effective treatment protocol for ARH is still lacking."

Several authors disclosed financial ties to pharmaceutical companies, including Aegerion, which partly funded the study.

Explore further: High-intensity statin effect independent of lipoprotein, CRP

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

High-intensity statin effect independent of lipoprotein, CRP

November 13, 2014
(HealthDay)—High-intensity statin therapy is associated with coronary atherosclerosis regression, regardless of baseline lipoprotein or C-reactive protein (CRP) levels, according to a study published in the Nov. 15 issue ...

Measuring plasma PCSK9 may ID resistance to PCSK9 inhibitors

November 29, 2017
(HealthDay)—Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) may help assess apparent resistance to PCSK9 inhibitors, according to a research letter published online Nov. 28 in the Annals of Internal ...

Many not treated according to 2013 cholesterol guidelines

November 25, 2014
(HealthDay)—Many patients are not being treated in accordance with the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines, according to a study published in the Dec. 2 issue ...

Atorvastatin/Ezetimibe beats atorvastatin after PCI

July 29, 2015
(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according to a study published in ...

Most younger adults with high LDL-C levels do not take a statin

January 4, 2017
Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a statin, according to a ...

Large variation in lipid reduction with high-dose statin tx

July 31, 2014
(HealthDay)—There is considerable interindividual variation in the magnitude of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) reductions achieved ...

Recommended for you

Rethinking the stroke rule 'time is brain'

August 13, 2018
In 1993, neurologist Camilo R. Gomez, MD, coined a phrase that for a quarter century has been a fundamental rule of stroke care: "Time is brain!"

High oxidative stress hampers males' production of powerful blood vessel dilator

August 13, 2018
Higher levels of oxidative stress in males results in lower levels of a cofactor needed to make the powerful blood vessel dilator nitric oxide, researchers report.

Epigenetic reprogramming of human hearts found in congestive heart failure

August 9, 2018
Congestive heart failure is a terminal disease that affects nearly 6 million Americans. Yet its management is limited to symptomatic treatments because the causal mechanisms of congestive heart failure—including its most ...

Older adults who get physical can lower their heart disease risk

August 8, 2018
Adults in their early 60s, who spend less time sitting and more time engaged in light to vigorous physical activity, benefit with healthier levels of heart and vessel disease markers, according to new research in Journal ...

Cardiac progenitor cells undergo a cell fate switch to build coronary arteries

August 7, 2018
Cells switch fates and acquire new identities during organogenesis and regeneration as a critical trait, although the mechanisms underlying such conversions are poorly understood. The vasculature provides a biological model ...

Taking a pill can effectively treat brutal lung disease

August 7, 2018
Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.